IL33 and psoriasis: Although the neutralization of IL-1RAcP affects the pathway induced by IL-1α, IL-1β and IL-33, its administration has positive effects in the control of the inflammation in OVA-induced allergic airway inflammation and Imiquimod-induced psoriasis.